189 related articles for article (PubMed ID: 21074478)
1. Dyskinesias do not develop after chronic intermittent levodopa therapy in clinically hemiparkinsonian rhesus monkeys.
Lieu CA; Deogaonkar M; Bakay RA; Subramanian T
Parkinsonism Relat Disord; 2011 Jan; 17(1):34-9. PubMed ID: 21074478
[TBL] [Abstract][Full Text] [Related]
2. Focal striatal dopamine may potentiate dyskinesias in parkinsonian monkeys.
Bankiewicz KS; Daadi M; Pivirotto P; Bringas J; Sanftner L; Cunningham J; Forsayeth JR; Eberling JL
Exp Neurol; 2006 Feb; 197(2):363-72. PubMed ID: 16337943
[TBL] [Abstract][Full Text] [Related]
3. Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model.
Di Monte DA; McCormack A; Petzinger G; Janson AM; Quik M; Langston WJ
Mov Disord; 2000 May; 15(3):459-66. PubMed ID: 10830409
[TBL] [Abstract][Full Text] [Related]
4. Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys.
Blanchet PJ; Konitsiotis S; Chase TN
Mov Disord; 1998 Sep; 13(5):798-802. PubMed ID: 9756148
[TBL] [Abstract][Full Text] [Related]
5. Blockade of cannabinoid type 1 receptors augments the antiparkinsonian action of levodopa without affecting dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys.
Cao X; Liang L; Hadcock JR; Iredale PA; Griffith DA; Menniti FS; Factor S; Greenamyre JT; Papa SM
J Pharmacol Exp Ther; 2007 Oct; 323(1):318-26. PubMed ID: 17630359
[TBL] [Abstract][Full Text] [Related]
6. Overlesioned hemiparkinsonian non human primate model: correlation between clinical, neurochemical and histochemical changes.
Oiwa Y; Eberling JL; Nagy D; Pivirotto P; Emborg ME; Bankiewicz KS
Front Biosci; 2003 Sep; 8():a155-66. PubMed ID: 12957824
[TBL] [Abstract][Full Text] [Related]
7. Brain α7 nicotinic acetylcholine receptors in MPTP-lesioned monkeys and parkinsonian patients.
Morissette M; Morin N; Grégoire L; Rajput A; Rajput AH; Di Paolo T
Biochem Pharmacol; 2016 Jun; 109():62-69. PubMed ID: 27038656
[TBL] [Abstract][Full Text] [Related]
8. α7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage.
Zhang D; McGregor M; Bordia T; Perez XA; McIntosh JM; Decker MW; Quik M
Mov Disord; 2015 Dec; 30(14):1901-1911. PubMed ID: 26573698
[TBL] [Abstract][Full Text] [Related]
9. The predictive validity of the drug-naive bilaterally MPTP-treated monkey as a model of Parkinson's disease: effects of L-DOPA and the D1 agonist SKF 82958.
Andringa G; Lubbers L; Drukarch B; Stoof JC; Cools AR
Behav Pharmacol; 1999 Mar; 10(2):175-82. PubMed ID: 10780830
[TBL] [Abstract][Full Text] [Related]
10. Investigating levodopa-induced dyskinesias in the parkinsonian primate.
Langston JW; Quik M; Petzinger G; Jakowec M; Di Monte DA
Ann Neurol; 2000 Apr; 47(4 Suppl 1):S79-89. PubMed ID: 10762135
[TBL] [Abstract][Full Text] [Related]
11. Changes in glutamate receptors in dyskinetic parkinsonian monkeys after unilateral subthalamotomy.
Jourdain VA; Morin N; Grégoire L; Morissette M; Di Paolo T
J Neurosurg; 2015 Dec; 123(6):1383-93. PubMed ID: 25932606
[TBL] [Abstract][Full Text] [Related]
12. [Dopa-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated hemiparkinsonian monkeys].
Chen S
Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1992 Feb; 25(1):50-2, 64. PubMed ID: 1591961
[TBL] [Abstract][Full Text] [Related]
13. Levodopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage.
Schneider JS
Pharmacol Biochem Behav; 1989 Sep; 34(1):193-6. PubMed ID: 2576311
[TBL] [Abstract][Full Text] [Related]
14. Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias.
Riahi G; Morissette M; Parent M; Di Paolo T
Eur J Neurosci; 2011 May; 33(10):1823-31. PubMed ID: 21501255
[TBL] [Abstract][Full Text] [Related]
15. AQW051, a novel and selective nicotinic acetylcholine receptor α7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys.
Di Paolo T; Grégoire L; Feuerbach D; Elbast W; Weiss M; Gomez-Mancilla B
Parkinsonism Relat Disord; 2014 Nov; 20(11):1119-23. PubMed ID: 25172125
[TBL] [Abstract][Full Text] [Related]
16. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).
Pearce RK; Jackson M; Smith L; Jenner P; Marsden CD
Mov Disord; 1995 Nov; 10(6):731-40. PubMed ID: 8749992
[TBL] [Abstract][Full Text] [Related]
17. The plasmalogen precursor analog PPI-1011 reduces the development of L-DOPA-induced dyskinesias in de novo MPTP monkeys.
Bourque M; Grégoire L; Di Paolo T
Behav Brain Res; 2018 Jan; 337():183-185. PubMed ID: 28917506
[TBL] [Abstract][Full Text] [Related]
18. A Selective Phosphodiesterase 10A Inhibitor Reduces L-Dopa-Induced Dyskinesias in Parkinsonian Monkeys.
Beck G; Maehara S; Chang PL; Papa SM
Mov Disord; 2018 May; 33(5):805-814. PubMed ID: 29508924
[TBL] [Abstract][Full Text] [Related]
19. Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides.
Tamim MK; Samadi P; Morissette M; Grégoire L; Ouattara B; Lévesque D; Rouillard C; Di Paolo T
Neuropharmacology; 2010 Jan; 58(1):286-96. PubMed ID: 19576910
[TBL] [Abstract][Full Text] [Related]
20. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys.
Papa SM; Chase TN
Ann Neurol; 1996 May; 39(5):574-8. PubMed ID: 8619541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
